source
- Eli Lilly signs up to $370M ion-channel collaboration with OmniAbEli Lilly has entered a collaboration with antibody platform company OmniAb that could involve up to $370 million in research, development and commercial milestone payments. OmniAb, which was spun…
- AstraZeneca halts phase 3 lung cancer trial of bispecific antibody volrustomig after it falls short of KeytrudaAstraZeneca stopped its phase 3 trial of the bispecific antibody volrustomig in metastatic non‑small cell lung cancer after interim data suggested the regimen would not meet the study's primary goa…